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In the previous issue of Critical Care, Yu and colleagues
report increased morbidity and mortality in patients
after myocardial infarction undergoing prophylactic
intra-aortic balloon pump support before coronary
artery bypass graft surgery. The impact of prophylactic
intra-aortic balloon pump implantation before coronary
artery bypass graft therapy still is controversially
debated. However, Yu and colleagues emphasize
further discussion and substantiate the need for a
prospective randomized controlled trial on this subject.rather than bleeding complications from IABP insertion.Yu and colleagues investigate in their well-conducted
retrospective analysis the impact of preoperative insertion
of an intra-aortic balloon pump (IABP) on postoperative
outcome in patients undergoing coronary artery bypass
graft (CABG) after acute myocardial infarction [1]. The
rationale for prophylactic IABP is to decrease the left
ventricular afterload and to improve coronary perfusion,
and thus to reduce the risk of perioperative low cardiac
output syndrome. In this study, preoperative IABP was
associated with increased morbidity, transfusion require-
ments and longer stay on the ICU postoperatively.
The use of prophylactic IABP in patients undergoing
CABG is based on data generated by Christenson and
colleagues in the late 1990s and early 2000s showing
positive effects of prophylactic IABP insertion on post-
operative short-term and long-term survival [2-5]. How-
ever, these positive results have been challenged in the
past few years by a number of retrospective analyses
showing conflicting results [6-9]. A recent prospective
randomized study by Ranucci and colleagues showed no
positive effect of prophylactic IABP in patients with
severely reduced left ventricular function undergoing* Correspondence: Philippe.grieshaber@chiru.med.uni-giessen.de
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we have addressed elsewhere [11].
The current study by Yu and colleagues revealed an
association between preoperative IABP and a prolonged
stay on the ICU. This result is not surprising, as post-
operative weaning from an IABP, which usually takes 24
to 48 hours, has to be performed under intensive care
monitoring. The composite morbidity endpoint was
reached more often in the IABP group. The authors also
observed increased transfusion requirements in the IABP
group that might, as the authors state, be related to
mechanical thrombocyte consumption and hemolysis
Increased transfusion of erythrocytes has been associated
with poor short-term and long-term outcome after cardiac
surgery in previous studies [12,13]. Interestingly, neither
increased transfusion nor the other parameters investi-
gated in this study influenced the overall length of hospital
stay and in-hospital mortality. Contrarily, the excellent
short-term mortality rates in both groups (control group,
1.0%; IABP group, 2.5%) suggest that this study population
did not represent a true high-risk patient collective.
On the one hand, Yu and colleagues’ study adds some
interesting results; on the other, numerous issues about
prophylactic IABP use still remain unanswered. The cur-
rent uncertainty about prophylactic IABP use in patients
undergoing CABG results from different aspects. In all
studies so far conducted, the criteria for prophylactic IABP
insertion were not well defined and were based on subject-
ive decisions by the treating physicians. Accordingly, the
term high-risk patient was based on very individual cri-
teria rather than on established tools for perioperative risk
estimation (for example, EuroSCORE, STS Risk Score).
The optimal timing of IABP insertion still is not known,
although some authors showed benefit from early inser-
tion [3,9]. However, the ideal length of temporization of
patients with myocardial infarction before CABG is also
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has to be judged in the context of the best-valued alterna-
tive therapy.
From a pathophysiological point of view, we suppose
that the effects of IABP (increased coronary perfusion,
reduction of left ventricular afterload) might induce the
greatest effect in patients with critically reduced coronary
perfusion and (temporarily) severely reduced left ventri-
cular function; that is, in patients with acute myocardial
infarction who need to be temporized prior to CABG. In
some institutions, including our clinic, prophylactic IABP
in these patients is initiated in the catheter laboratory or,
at the latest, after admission to the ICU. The patients, if
hemodynamically stable and without ongoing symptoms,
are then temporized until cardiac enzymes are recurrent,
which usually takes 2 to 3 days. However, regarding the
paucity of good and contemporary data on the value of
prophylactic IABP, this clinical routine lacks evidence.
The best way to obtain evidence and to generate reliable
guidelines for the prophylactic use of IABP in patients
undergoing CABG is an adequately powered prospective
randomized controlled trial with a well-defined study
population, with a standardized protocol for perioperative
care and IABP handling and with a clinically relevant
and appropriate primary endpoint (for example, 30-day
mortality).
Abbreviations
CABG: Coronary artery bypass graft; IABP: Intra-aortic balloon pump.
Competing interests
The authors declare that they have no competing interests.
Acknowledgements
PG and AB received research support from The German Heart Foundation,
the University Hospital Giessen and Marburg Research Fund. PG is currently
initiating a prospective trial on prophylactic IABP.
References
1. Yu P-J, Cassiere HA, Dellis SL, Kohn N, Manetta F, Hartman AR:
Propensity-matched analysis of the effect of preoperative intraaortic
balloon pump in coronary artery bypass grafting after recent acute
myocardial infarction on postoperative outcomes. Crit Care 2014, 18:531.
2. Christenson JT, Badel P, Simonet F, Schmuziger M: Preoperative intraaortic
balloon pump enhances cardiac performance and improves the
outcome of redo CABG. Ann Thorac Surg 1997, 64:1237–1244.
3. Christenson JT, Simonet F, Badel P, Schmuziger M: Optimal timing of
preoperative intraaortic balloon pump support in high-risk coronary
patients. Ann Thorac Surg 1999, 68:934–939.
4. Christenson JT, Cohen M, Ferguson JJ 3rd, Freedman RJ, Miller MF,
Ohman EM, Reddy RC, Stone GW, Urban PM: Trends in intraaortic balloon
counterpulsation complications and outcomes in cardiac surgery.
Ann Thorac Surg 2002, 74:1086–1090. discussion 1090–1091.
5. Christenson JT, Licker M, Kalangos A: The role of intra-aortic counterpulsation
in high-risk OPCAB surgery. J Card Surg 2003, 18:286–294.
6. Miceli A, Fiorani B, Danesi TH, Melina G, Sinatra R: Prophylactic intra-aortic
balloon pump in high-risk patients undergoing coronary artery bypass
grafting: a propensity score analysis. Interact Cardiovasc Thorac Surg 2009,
9:291–294.7. Qiu Z, Chen X, Xu M, Jiang Y, Xiao L, Liu L, Wang L: Evaluation of
preoperative intra-aortic balloon pump in coronary patients with severe
left ventricular dysfunction undergoing OPCAB surgery: early and
mid-term outcomes. J Cardiothorac Surg 2009, 4:39.
8. Santarpino G, Onorati F, Rubino AS, Abdalla K, Caroleo S, Santangelo E,
Renzulli A: Preoperative intraaortic balloon pumping improves outcomes
for high-risk patients in routine coronary artery bypass graft surgery.
Ann Thorac Surg 2009, 87:481–488.
9. Böning A, Buschbeck S, Roth P, Scheibelhut C, Bödeker RH, Brück M,
Niemann B: IABP before cardiac surgery: clinical benefit compared to
intraoperative implantation. Perfusion 2013, 28:103–108.
10. Ranucci M, Castelvecchio S, Biondi A, de Vincentiis C, Ballotta A, Varrica A,
Frigiola A, Menicanti L, Surgical and Clinical Outcome Research (SCORE)
Group: A randomized controlled trial of preoperative intra-aortic
balloon pump in coronary patients with poor left ventricular function
undergoing coronary artery bypass surgery. Crit Care Med 2013,
41:2476–2483.
11. Grieshaber P, Böning A: Prophylactic intra-aortic balloon counterpulsation
in cardiac surgery: challenges in planning the ‘right’ trial. Crit Care Med
2014, 42:e246–247.
12. Koch CG, Li L, Duncan AI, Mihaljevic T, Loop FD, Starr NJ, Blackstone EH:
Transfusion in coronary artery bypass grafting is associated with
reduced long-term survival. Ann Thorac Surg 2006, 81:1650–1657.
13. Loor G, Li L, Sabik JF 3rd, Rajeswaran J, Blackstone EH, Koch CG: Nadir
hematocrit during cardiopulmonary bypass: end-organ dysfunction and
mortality. J Thorac Cardiovasc Surg 2012, 144:654–662. e4.
14. Lee DC, Oz MC, Weinberg AD, Ting W: Appropriate timing of surgical
intervention after transmural acute myocardial infarction. J Thorac
Cardiovasc Surg 2003, 125:115–120.
15. Caceres M, Weiman DS: Optimal timing of coronary artery bypass grafting
in acute myocardial infarction. Ann Thorac Surg 2013, 95:365–372.
16. Weiss ES, Chang DD, Joyce DL, Nwakanma LU, Yuh DD: Optimal timing of
coronary artery bypass after acute myocardial infarction: a review of
California discharge data. J Thorac Cardiovasc Surg 2008, 135:503–511. e3.
doi:10.1186/s13054-014-0662-2
Cite this article as: Grieshaber et al.: Prophylactic intra-aortic balloon
counterpulsation in cardiac surgery: it is time for clear evidence. Critical
Care 2014 18:662.
